Nilotinib Capsules, 200 mg per capsule, packaged in cartons, Rx only, Manufactured for: Cipla USA...
FDA Drug Recall #D-0382-2026 — Class III — February 18, 2026
Recall Summary
| Recall Number | D-0382-2026 |
| Classification | Class III — Low risk |
| Date Initiated | February 18, 2026 |
| Status | Ongoing |
| Voluntary | Voluntary: Firm initiated |
Recalling Firm
| Firm | Cipla USA, Inc. |
| Location | Warren, NJ |
| Product Type | Drugs |
| Quantity | 164 cartons |
Product Description
Nilotinib Capsules, 200 mg per capsule, packaged in cartons, Rx only, Manufactured for: Cipla USA, Inc., 10 Independence Boulevard, Suite 300, Warren, NJ 07059, Outer carton: 112 capsules (4 individual packs containing 28 capsules each), NDC 69097-032-74; Inner carton: 28 capsules (4 blisters of 7 capsules), NDC 69097-032-56; Foil blister: NDC 69097-032-17
Reason for Recall
Failed Tablet/Capsule Specifications: Observed OOS results at 6-months long-term stability condition for Description test and Appearance by Visual Inspection test.
Distribution Pattern
U.S.A. Nationwide
Lot / Code Information
Lot #: 5GJ0223, Exp 04/30/2027
Other Recalls from Cipla USA, Inc.
| Recall # | Classification | Product | Date |
|---|---|---|---|
| D-0451-2026 | Class II | Cinacalcet Hydrochloride Tablets, 90 mg, 30 Tab... | Mar 16, 2026 |
| D-0450-2026 | Class II | Cinacalcet Hydrochloride Tablets, 60 mg, 30 Tab... | Mar 16, 2026 |
| D-0449-2026 | Class II | Cinacalcet Hydrochloride Tablets, 30 mg, 30 Tab... | Mar 16, 2026 |
| D-0423-2026 | Class II | Lanreotide Injection, 120 mg/0.5 mL, Box contai... | Mar 13, 2026 |
| D-0422-2026 | Class II | Lanreotide Injection, 120 mg*/0.5 mL, Box conta... | Mar 13, 2026 |
Frequently Asked Questions
Stop taking the medication and contact your pharmacist or doctor immediately. For Class I recalls, this is urgent. For Class II or III recalls, consult your doctor before stopping — abruptly discontinuing certain medications (blood pressure drugs, antidepressants, diabetes medications) can be more harmful than continuing while arranging a replacement. Check whether the recall applies to your specific lot number and expiration date. Return the product to your pharmacy and report any adverse effects to FDA MedWatch at 1-800-FDA-1088.
Not necessarily. Many drug recalls are initiated because of quality system failures or test results that suggest a product might not meet specifications — even if no patients have reported harm. The FDA uses a precautionary approach: if there is reason to believe quality standards were not met, a recall is required regardless of whether adverse effects have been reported. Class I recalls typically involve a reasonable probability of harm; Class II recalls may cause temporary health issues; Class III recalls are for products unlikely to cause adverse health consequences but that still violate regulations.
Pharmacies typically receive recall notices directly from drug wholesalers and manufacturers within days of the recall being announced. Your pharmacist can look up whether any product in your prescription history matches a recalled lot number. For current recalls, the FDA publishes updates at FDA.gov/safety/recalls-market-withdrawals-safety-alerts and sends MedWatch email alerts for significant drug safety issues. You can sign up for MedWatch alerts at FDA.gov. Most major pharmacy chains also have their own recall notification systems that automatically alert pharmacists when a recalled product is in their inventory.
What Should You Do?
Stop using this medication if affected by this recall. Contact your pharmacist or prescribing doctor immediately for guidance. Do not flush medications — use a drug take-back program.